HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, March 28, 2012 (HealthDay News) -- Growth of the deadly skin cancer melanoma may be triggered by the immune system turning on itself, according to a new study that also identified the mechanism that causes this to happen.
Melanoma accounts for only about 5 percent of skin cancers, but is the cause of most skin cancer deaths, American Cancer Society statistics indicate. The disease is often curable in its early stages but is difficult to treat once it has spread invasively, the authors of the new study noted.
The study, published in the current edition of the journal Science Translational Medicine, focused on a specific immune-inhibiting molecule called B7-H1 in melanoma tumors.
In patients with tumors that expressed B7-H1, suppression of the inflammatory immune response sped the growth and increased the aggressiveness of their tumors, the researchers from Yale School of Medicine and Johns Hopkins Medical Institutions found.
The investigators also found that tumor cells somehow use a component of the immune system itself (interferon gamma) to turn on B7-H1 and suppress the immune system.
"We were surprised to find that aggressive tumors can not only escape or hide from infiltrating immune cells, but can go on the attack -- using interferon gamma as a weapon against the immune system," lead author Dr. Lieping Chen, a professor of immunobiology at Yale School of Medicine and director of the cancer immunology program at Yale Cancer Center, said in a Yale news release.
This mechanism may be responsible for immune suppression and tumor growth in up to 40 percent of melanoma patients, Chen said. The finding may make it possible to develop therapies that block this immune-suppressing ability, he added.
The American Cancer Society has more about melanoma.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on June 05, 2022